Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMUTAMYCIN (mitomycin) by Bristol Myers Squibb is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 1981.
Drug data last refreshed 18h ago
Alkylating Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C
Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
Worked on MUTAMYCIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo